AP
UTHR icon

AHL Partners’s United Therapeutics UTHR Stock Holding History

AHL Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$3.27M Sell
22,123
-30,178
-58% -$3.84M 0.05% 593
2017
Q3 		$6.13M Buy
52,301
+17,515
+50% +$2.24M 0.11% 332
2017
Q2 		$4.51M Buy
34,786
+14,057
+68% +$1.75M 0.1% 390
2017
Q1 		$2.81M Buy
20,729
+7,346
+55% +$1.11M 0.06% 533
2016
Q4 		$1.92M Buy
13,383
+4,199
+46% +$536K 0.06% 520
2016
Q3 		$1.08M Buy
9,184
+3,363
+58% +$404K 0.04% 572
2016
Q2 		$617K Buy
5,821
+2,482
+74% +$277K 0.03% 562
2016
Q1 		$372K Sell
3,339
-13,101
-80% -$1.66M 0.02% 627
2015
Q4 		$2.58M Buy
16,440
+13,877
+541% +$2.02M 0.2% 190
2015
Q3 		$336K Sell
2,563
-26,928
-91% -$4.32M 0.05% 527
2015
Q2 		$5.13M Sell
29,491
-1,282
-4% -$231K 0.2% 171
2015
Q1 		$5.31M Buy
30,773
+10,787
+54% +$1.64M 0.21% 153
2014
Q4 		$2.59M Buy
+19,986
New +$2.58M 0.13% 327

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AHL Partners's UTHR Position: Q4 2017 in Review

AHL Partners reduced its United Therapeutics (UTHR) stake by 58% in Q4 2017, selling an estimated $3.84M and leaving 22,123 shares worth $3.27M. The position accounts for 0.05% of the portfolio, ranked #593.

AHL Partners first reported a position in UTHR in Q4 2014 and has held it in 13 quarters since. The position peaked at $6.13M in Q3 2017. 400 funds tracked by Wall St. Rank hold UTHR as of Q4 2017.

  • AHL Partners held 22,123 shares of United Therapeutics worth $3.27M as of Q4 2017.
  • AHL Partners sold 30,178 United Therapeutics shares in Q4 2017, an estimated $3.84M.
  • United Therapeutics made up 0.05% of AHL Partners's portfolio in Q4 2017, its #593 holding.
  • AHL Partners first reported a position in United Therapeutics in Q4 2014 and has held it in 13 quarters since.
  • AHL Partners's United Therapeutics position peaked at $6.13M in Q3 2017.
  • 400 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.